| 证券代码 | NXTM.O |
| 证券名称 | NxStage Medical Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2005-10-27 |
| 首发价格(元) | 10 USD |
| 首发数量(股) | 5500000 |
| 首发募资额(元) | 55,000,000.00 USD |
| 首发主承销商 | Merrill Lynch, Pierce, Fenner and Smith Incorporated |
| 货币单位 | USD |
| 公司名称 | NxStage Medical, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 350 Merrimack Street, Lawrence, Massachusetts, USA |
| 成立日期 | 1998-12 |
| 董事会主席 | Robert G. Funari |
| 公司属地 | United States 美国 |
| 公司网址 | www.nxstage.com |
| 电话 | +1 (978) 687-4700 |
| 传真 | - |
| 公司简介 | NxStage Medical, Inc. (Nasdaq: NXTM) is a leading medical technology company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease (ESRD) and acute kidney failure. NxStage has also established a small number of dialysis clinics committed to the development of innovative care delivery models for patients with ESRD. |